Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 391 articles:
HTML format
Text format



Single Articles


    June 2018
  1. HSIEH YH, Patel AV, Loevinsohn GS, Thomas DL, et al
    Emergency Departments at the Crossroads of Intersecting Epidemics (HIV, HCV, Injection Drug Use, and Opioid Overdose) - Estimating HCV Incidence in an Urban Emergency Department Population.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12948.
    PubMed     Text format     Abstract available


  2. KUMAR R
    Hepatitis B Virus Infection and Diabetes Mellitus: An Adverse Relationship.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12949.
    PubMed     Text format     Abstract available


  3. ZHOU TC, Li X, Chen LJ, Fan JH, et al
    Differential expression profile of hepatic circular RNAs in chronic hepatitis B.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12944.
    PubMed     Text format     Abstract available


  4. LUTTERKORT GL, Wranke A, Hengst J, Yurdaydin C, et al
    Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12947.
    PubMed     Text format     Abstract available


  5. HARIDY J, Wigg A, Muller K, Ramachandran J, et al
    Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12943.
    PubMed     Text format     Abstract available


    May 2018
  6. LIU Z, Yang Q, Shi O, Ye W, et al
    The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: an observational population based study.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12938.
    PubMed     Text format     Abstract available


  7. KRAMER JR, Puenpatom A, Erickson K, Cao Y, et al
    Real-World Effectiveness of Elbasvir/Grazoprevir in HCV-Infected Patients in the US Veterans Affairs Healthcare System.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12937.
    PubMed     Text format     Abstract available


  8. AISYAH DN, Shallcross L, Hayward A, Aldridge RW, et al
    Hepatitis C among Vulnerable Populations: A Seroprevalence Study of Homeless, People Who Inject Drugs and Prisoners in London.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12936.
    PubMed     Text format     Abstract available


  9. MARCO A, Roget M, Cervantes M, Forne M, et al
    Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and non-inmates.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12940.
    PubMed     Text format     Abstract available


  10. ZHOU Y, Zhou YH
    Is revaccination required in children who received a full primary vaccination against hepatitis B in infancy?
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12941.
    PubMed     Text format     Abstract available


  11. AGARWAL K, Ahn SH, Elkhashab M, Lau AH, et al
    Safety and Efficacy of Vesatolimod (GS-9620) in Patients with Chronic Hepatitis B Who Are Not Currently on Antiviral Treatment.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12942.
    PubMed     Text format     Abstract available


  12. JACKSON C, Gunson RN, Bradley-Stewart A, Bennet S, et al
    Epidemiology and patient characteristics of hepatitis D virus infection in the West of Scotland 2011-2016.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12939.
    PubMed     Text format     Abstract available


  13. FUJITA M, Sugiyama M, Sato Y, Nagashima K, et al
    Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12933.
    PubMed     Text format     Abstract available


  14. JEONG Y, Jin B, Lee HW, Park HJ, et al
    Evolution and Persistence of the Resistance-Associated Substitutions of Hepatitis C Virus after Direct-Acting Antiviral Treatment Failures.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12932.
    PubMed     Text format     Abstract available


  15. AKRAM A, Islam SMR, Munshi SU, Tabassum S, et al
    Detection of Hepatitis B Virus DNA among Chronic and potential Occult HBV patients in resource-limited settings by Loop-Mediated Isothermal Amplification assay.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12931.
    PubMed     Text format     Abstract available


  16. CARDOSO AC, Perez RM, de Figueiredo-Mendes C, Carvalho Leite N, et al
    Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with Controlled Attenuation Parameter (CAP).
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12930.
    PubMed     Text format     Abstract available


  17. DEMING R, Ford MM, Moore MS, Lim S, et al
    Evaluation of a hepatitis C clinical care coordination program's effect on treatment initiation and cure: A surveillance-based propensity score matching approach.
    J Viral Hepat. 2018 May 14. doi: 10.1111/jvh.12929.
    PubMed     Text format     Abstract available


  18. CHENG CY, Wu HH, Zou H, Lo YC, et al
    Epidemiological characteristics and associated factors of acute hepatitis A outbreak among HIV-coinfected men who have sex with men in Taiwan, June 2015-December 2016.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12926.
    PubMed     Text format     Abstract available


  19. CHO YY, Lee JH, Chang Y, Nam JY, et al
    Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12927.
    PubMed     Text format     Abstract available


  20. ZHOU TC, Lai X, Feng MH, Tang Y, et al
    Systematic review and meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12928.
    PubMed     Text format     Abstract available


  21. WANG J, Xia J, Zhang R, Yan X, et al
    A novel index using routinely clinical parameters for predicting significant liver inflammation in chronic hepatitis B.
    J Viral Hepat. 2018 May 9. doi: 10.1111/jvh.12925.
    PubMed     Text format     Abstract available


    April 2018
  22. CHI H, Japhary A, de Man RA, de Knegt RJ, et al
    Younger Age and Language Barriers are Associated with Non-adherence to Clinical Follow-up in Hepatitis B Treatment.
    J Viral Hepat. 2018 Apr 21. doi: 10.1111/jvh.12920.
    PubMed     Text format     Abstract available


  23. MARTINELLO M, Bhagani S, Gane E, Orkin C, et al
    Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917.
    PubMed     Text format     Abstract available


  24. NFOR ON, Wu MF, Debnath T, Lee CT, et al
    Hepatitis B virus infection in Taiwan: The role of NTCP rs2296651 variant in relation to sex.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12912.
    PubMed     Text format     Abstract available


  25. BOYD A, Moh R, Maylin S, Chekaraou MA, et al
    Precore G1896A mutation is associated with reduced rates of HBsAg-seroclearance in treated HIV-hepatitis B virus co-infected patients from Western Africa.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12914.
    PubMed     Text format     Abstract available


  26. WADE AJ, McCormack A, Roder C, McDonald K, et al
    Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12910.
    PubMed     Text format     Abstract available


  27. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs; the case of France.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12919.
    PubMed     Text format     Abstract available


  28. CAREY I, Byrne R, Childs K, Horner M, et al
    Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12916.
    PubMed     Text format     Abstract available


  29. GENCAY M, Seffner A, Pabinger S, Gautier J, et al
    Detection of in vivo hepatitis B virus surface antigen mutations - a comparison of four routine screening assays.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12915.
    PubMed     Text format     Abstract available


  30. ANGELIDAKIS G, Hwang JP, Dandachi D, Economides MP, et al
    Universal screening for hepatitis C: a needed approach in patients with hematologic malignancies.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12913.
    PubMed     Text format     Abstract available


  31. YOO SH, Kwon JH, Nam SW, Kim HY, et al
    Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: comparison with pegylated interferon-based therapy in chronic hepatitis C patients.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12918.
    PubMed     Text format     Abstract available


  32. KOC OM, Savelkoul PHM, van Loo IHM, Peeters A, et al
    Safety and immunogenicity of HBAI20 Hepatitis B vaccine in healthy naive and non-responding adults.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12909.
    PubMed     Text format     Abstract available


  33. KUANG XJ, Jia RR, Huo RR, Yu JJ, et al
    Systematic review of risk factors of hepatocellular carcinoma after Hepatitis B Surface Antigen seroclearance.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12905.
    PubMed     Text format     Abstract available


  34. SRIDHAR S
    Use of S17 fragment containing hepatitis E virus infectious clones in cell culture experiments: the fine print does matter.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12902.
    PubMed     Text format     Abstract available


  35. TANG X, Allain JP, Wang H, Rong X, et al
    Incidence of HBV infection in young Chinese blood donors born after mandatory implementation of neonatal hepatitis B vaccination nationwide.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12901.
    PubMed     Text format     Abstract available


  36. WISLOFF T, White R, Dalgard O, Amundsen EJ, et al
    Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12904.
    PubMed     Text format     Abstract available


  37. SCHNELL G, Tripathi R, Beyer J, Reisch T, et al
    Characterization of Demographics and NS5A Genetic Diversity for HCV Genotype 4-Infected Patients with or without Cirrhosis Treated with Ombitasvir/Paritaprevir/Ritonavir.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12906.
    PubMed     Text format     Abstract available


  38. MOORE MS, Bocour A, Winters A
    Dialysis Facility Screening and Testing Practices in the Era of Improved Hepatitis C Treatment.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12907.
    PubMed     Text format     Abstract available


  39. PENG Z, Hong-Bo D, Guang-Dong T, Xiao-Ke L, et al
    Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation: a multicentre perspective in China.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12903.
    PubMed     Text format     Abstract available


    March 2018
  40. GODOY P, Carmona G, Manzanares S, Jane M, et al
    Trends and risk factors of hepatitis A in Catalonia after the introduction of a hepatitis A+B vaccination program.
    J Viral Hepat. 2018 Mar 31. doi: 10.1111/jvh.12900.
    PubMed     Text format     Abstract available


  41. RICCO G, Popa DC, Cavallone D, Iacob S, et al
    Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12895.
    PubMed     Text format     Abstract available


  42. HOSHINO K, Sugiyama M, Date T, Maruwaka S, et al
    Phylogenetic and phylodynamic analysis of hepatitis C virus subtype 1a in Okinawa, Japan.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12898.
    PubMed     Text format     Abstract available


  43. WANG H, Swann R, Thomas E, Innes HA, et al
    Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12897.
    PubMed     Text format     Abstract available


  44. BOYD SD, Harrington P, Komatsu TE, Naeger LK, et al
    HCV Genotype 4, 5, and 6: Distribution of Viral Subtypes and Sustained Virologic Response Rates in Clinical Trials of Approved Direct-acting Antiviral Regimens.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12896.
    PubMed     Text format     Abstract available


  45. NJOUOM R, Siffert I, Texier G, Lachenal G, et al
    The burden of Hepatitis C virus in Cameroon: Spatial epidemiology and historical perspective.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12894.
    PubMed     Text format     Abstract available


  46. GOOSSENS N, de Vito C, Mangia A, Clement S, et al
    Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12891.
    PubMed     Text format     Abstract available


  47. LI M, Gan Y, Fan C, Yuan H, et al
    Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12892.
    PubMed     Text format     Abstract available


  48. FEDELI U
    Increasing mortality associated with the more recent epidemic wave of Hepatitis C virus infection in Northern Italy.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12893.
    PubMed     Text format     Abstract available


  49. PAPATHEODORIDIS GV, Hatzakis A, Cholongitas E, Baptista-Leite R, et al
    Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    J Viral Hepat. 2018;25 Suppl 1:6-17.
    PubMed     Text format     Abstract available


    February 2018
  50. DUARTE G, Williams CJ, Vasconcelos P, Nogueira P, et al
    Capacity to report on mortality attributable to chronic Hepatitis B and C infections by Member States: an exercise to monitor progress toward viral hepatitis elimination.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12882.
    PubMed     Text format     Abstract available


  51. MACLEAN CD, Berger C, Cangiano ML, Ziegelman D, et al
    Impact of Electronic Reminder Systems on Hepatitis C Screening in Primary Care.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12885.
    PubMed     Text format     Abstract available


  52. CHEN JY, Ren Y, Yan P, Belina ME, et al
    Tricyclic Antidepressant Use and the Risk of Fibrosis Progression in Hepatitis C-Infected Persons: Results from ERCHIVES.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12884.
    PubMed     Text format     Abstract available


  53. LI J, Zhang T, Gordon SC, Rupp LB, et al
    Impact of sustained virological response on risk of type 2 diabetes among hepatitis C patients in the US.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12887.
    PubMed     Text format     Abstract available


  54. YOUNOSSI ZM, Tanaka A, Eguchi Y, Henry L, et al
    Treatment of Hepatitis C Virus Leads to Economic Gains Related to Reduction in Cases of Hepatocellular Carcinoma and Decompensated Cirrhosis in Japan.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12886.
    PubMed     Text format     Abstract available


  55. OLVEIRA A, Dominguez L, Troya J, Arias A, et al
    Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12883.
    PubMed     Text format     Abstract available


  56. CACOUB P, Buggisch P, Carrion JA, S Cooke G, et al
    Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Infection in Europe.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12881.
    PubMed     Text format     Abstract available


  57. LEE WC, Chou HS, Lee CS, Wu TH, et al
    Viral activity and outcome of hepatitis B surface antigen-positive grafts in deceased liver transplantation.
    J Viral Hepat. 2018 Feb 12. doi: 10.1111/jvh.12880.
    PubMed     Text format     Abstract available


  58. CORTESI PA, Belli LS, Facchetti R, Mazzarelli C, et al
    The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12877.
    PubMed     Text format     Abstract available


  59. HEDENSTIERNA M, Nangarhari A, El-Sabini A, Weiland O, et al
    Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virologic response in chronic hepatitis C.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12879.
    PubMed     Text format     Abstract available


  60. DELFINO CM, Cerrudo CS, Biglione M, Oubina JR, et al
    A comprehensive bioinformatic analysis of hepatitis D virus (HDV) full-length genomes.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12876.
    PubMed     Text format     Abstract available


  61. ZHONG GC, Wu YL, Hao FB, Rao XW, et al
    Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case-control study with propensity score analysis.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12878.
    PubMed     Text format     Abstract available


  62. ZAKARIA HM, Salem TA, El-Araby HA, Salama RM, et al
    Steroid therapy in children with fulminant hepatitis A.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12873.
    PubMed     Text format     Abstract available


  63. PREDA CM, Popescu CP, Baicus C, Constantinescu I, et al
    Risk of HBV reactivation in HBV+HCV coinfected patients with compensated liver cirrhosis treated with Ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12872.
    PubMed     Text format     Abstract available


  64. LUXENBURGER H, Grass F, Baermann J, Boettler T, et al
    Differential virus-specific CD8(+) T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12874.
    PubMed     Text format     Abstract available


  65. WALKER AJ, Peacock CJ, Pedergnana V, Irving WL, et al
    Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12871.
    PubMed     Text format     Abstract available


    January 2018
  66. ALVAREZ-OSSORIO MJ, Sarmento E Castro R, Granados R, Macias J, et al
    Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12867.
    PubMed     Text format     Abstract available


  67. GUPTA S, Rout G, Patel AH, Mahanta M, et al
    Efficacy of Generic Oral Directly Acting Agents in Patients with Hepatitis C Virus Infection.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12870.
    PubMed     Text format     Abstract available


  68. FABER M, Willrich N, Schemmerer M, Rauh C, et al
    Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12868.
    PubMed     Text format     Abstract available


  69. HARRIS M, Bonnington O, Harrison G, Hickman M, et al
    Understanding hepatitis C intervention success: Qualitative findings from the HepCATT study.
    J Viral Hepat. 2018 Jan 25. doi: 10.1111/jvh.12869.
    PubMed     Text format     Abstract available


  70. YANG C, Yu W, Bi Y, Long F, et al
    Increased estradiol in hepatitis E virus infected pregnant women promote viral replication.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12865.
    PubMed     Text format     Abstract available


  71. ZHOU PP, Xu J, Dai MJ, Shi YY, et al
    The immunosuppressive effects of CD4(+) CD25(+) regulatory T cells on dendritic cells in patients with chronic hepatitis B.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12863.
    PubMed     Text format     Abstract available


  72. AYOUB HH, Al Kanaani Z, Abu-Raddad LJ
    Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12864.
    PubMed     Text format     Abstract available


  73. AISYAH DN, Shallcross L, Hully AJ, O'Brien A, et al
    Assessing Hepatitis C Spontaneous Clearance and Understanding Associated Factors: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12866.
    PubMed     Text format     Abstract available


  74. COLOMBO M, Boccaccio V
    Hepatitis C eradication with DAA and risk of liver cancer recurrence: the debate unrests.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12862.
    PubMed     Text format     Abstract available


  75. CHO H, Ahn H, Lee DH, Lee JH, et al
    Entecavir and Tenofovir Reduce Hepatitis B Virus-related Hepatocellular Carcinoma Recurrence More Effectively than Other Antivirals.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12855.
    PubMed     Text format     Abstract available


  76. LAU KC, Osiowy C, Giles E, Lusina B, et al
    Deep Sequencing Shows Low Level Oncogenic Hepatitis B Virus Variants Persisting Post-Liver Transplant Despite Potent Anti-HBV Prophylaxis.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12860.
    PubMed     Text format     Abstract available


  77. FLISIAK R, Zarebska-Michaluk D, Janczewska E, Staniaszek A, et al
    Treatment of HCV infection in Poland at the beginning of the interferon-free era - the EpiTer-2 study.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12861.
    PubMed     Text format     Abstract available


  78. YOUNG K, Haq K, MacLean S, Dudani R, et al
    Development of a recombinant murine tumor model using hepatoma cells expressing hepatitis C virus (HCV) non-structural antigens.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12856.
    PubMed     Text format     Abstract available


  79. FALADE-NWULIA O, Sulkowski MS, Merkow A, Latkin C, et al
    Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12859.
    PubMed     Text format     Abstract available


  80. SCHUTZ A, Moser S, Schwanke C, Schubert R, et al
    Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk for non-adherence to direct-acting antivirals.
    J Viral Hepat. 2018 Jan 5. doi: 10.1111/jvh.12857.
    PubMed     Text format     Abstract available


    December 2017
  81. EL KASSAS M, Funk AL, Salaheldin M, Shimakawa Y, et al
    Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12854.
    PubMed     Text format     Abstract available


  82. SULKOWSKI MS, Feld JJ, Lawitz E, Felizarta F, et al
    Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12853.
    PubMed     Text format     Abstract available


  83. HAJARIZADEH B, Grebely J, Matthews GV, Martinello M, et al
    Uptake of direct acting antiviral treatment for chronic hepatitis C in Australia.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12852.
    PubMed     Text format     Abstract available


  84. CHEN CH, Hsu YC, Lu SN, Hung CH, et al
    The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12851.
    PubMed     Text format     Abstract available


  85. KOZUKA R, Hai H, Motoyama H, Hagihara A, et al
    The Presence of Multiple NS5A RASs is Associated with the Outcome of Sofosbuvir and Ledipasvir Therapy in NS5A Inhibitor-Naive Patients with Chronic HCV Genotype 1b Infection in a Real-World Cohort.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12850.
    PubMed     Text format     Abstract available


  86. MCNAUGHTON AL, Sreenu VB, Wilkie G, Gunson R, et al
    Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12849.
    PubMed     Text format     Abstract available


  87. GUBAY F, Staunton R, Metzig C, Abubakar I, et al
    Assessing uncertainty in the burden of Hepatitis C Virus: comparison of estimated disease burden and treatment costs in the UK.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12847.
    PubMed     Text format     Abstract available


  88. ZENG QL, Xu GH, Wang B, Li ZQ, et al
    Prophylactic antiviral therapy for the prevention of mother-to-child transmission of hepatitis B virus can be stopped at delivery.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12848.
    PubMed     Text format     Abstract available


  89. SIMMONS R, Ireland G, Irving W, Hickman M, et al
    Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12844.
    PubMed     Text format     Abstract available


  90. RODRIGUEZ DE SANTIAGO E, Velazquez Kennedy K, Garcia Gonzalez M, Gea Rodriguez F, et al
    HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12843.
    PubMed     Text format     Abstract available


  91. READ SA, Parnell G, Booth D, Douglas MW, et al
    The Antiviral Role of Zinc and Metallothioneins in Hepatitis C Infection.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12845.
    PubMed     Text format     Abstract available


  92. ERMAN A, Sathya A, Nam A, Bielecki JM, et al
    Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12846.
    PubMed     Text format     Abstract available


  93. LIU DP, Lu W, Zhang ZQ, Wang YB, et al
    Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B.
    J Viral Hepat. 2017 Dec 12. doi: 10.1111/jvh.12842.
    PubMed     Text format     Abstract available


  94. FERREIRA GLC, Marano C, De Moerlooze L, Guignard A, et al
    Incidence and prevalence of hepatitis B in patients with diabetes mellitus in the UK: a population-based cohort study using the UK Clinical Practice Research Datalink.
    J Viral Hepat. 2017 Dec 8. doi: 10.1111/jvh.12841.
    PubMed     Text format     Abstract available


  95. NAM JY, Chang Y, Cho H, Kang SH, et al
    Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
    J Viral Hepat. 2017 Dec 1. doi: 10.1111/jvh.12838.
    PubMed     Text format     Abstract available


    November 2017
  96. CHEN Y, Xie C, Zhang Y, Li Y, et al
    Knowledge regarding Hepatitis B Mother-to-child Transmission among Healthcare Workers in South China.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12839.
    PubMed     Text format     Abstract available


  97. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12837.
    PubMed     Text format     Abstract available


  98. TAMORI A, Abiru S, Enomoto H, Kioka K, et al
    Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12840.
    PubMed     Text format     Abstract available


  99. CARLTON-SMITH C, Holmes JA, Naggie S, Lidofsky A, et al
    IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
    J Viral Hepat. 2017 Nov 29. doi: 10.1111/jvh.12836.
    PubMed     Text format     Abstract available


  100. WANG Y, Liang X, Yang J, Wang H, et al
    Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of non-advanced liver fibrosis for chronic hepatitis B.
    J Viral Hepat. 2017 Nov 29. doi: 10.1111/jvh.12835.
    PubMed     Text format     Abstract available


  101. LIU J, Zhang S, Liu M, Wang Q, et al
    Distribution of ABO/Rh blood groups and their association with hepatitis B virus infection in 3.8 million Chinese adults: a population-based cross-sectional study.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12829.
    PubMed     Text format     Abstract available


  102. LEE HR, Cho YY, Lee GY, You DG, et al
    A direct role for hepatitis B virus X protein in inducing mitochondrial membrane permeabilization.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12831.
    PubMed     Text format     Abstract available


  103. YOUNOSSI ZM, Stepanova M, Schwarz KB, Wirth S, et al
    Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12830.
    PubMed     Text format     Abstract available


  104. JENG WJ, Chen YC, Liaw YF
    Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12833.
    PubMed     Text format     Abstract available


  105. TANAKA J, Akita T, Ohisa M, Sakamune K, et al
    Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12828.
    PubMed     Text format     Abstract available


  106. HU Y, Xu C, Xu B, Hu L, et al
    Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: a multicenter prospective cohort study.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12834.
    PubMed     Text format     Abstract available


  107. HSU YC, Ho HJ, Lee TY, Huang YT, et al
    Temporal Trend and Risk Determinants of Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Entecavir or Tenofovir.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12832.
    PubMed     Text format     Abstract available


  108. KEISER O, Giudici F, Mullhaupt B, Junker C, et al
    Trends in hepatitis C-related mortality in Switzerland.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12803.
    PubMed     Text format     Abstract available


  109. BROWN A, Hezode C, Zuckerman E, Foster GR, et al
    Efficacy and safety of 12 weeks of elbasvir +/- grazoprevir +/- ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12801.
    PubMed     Text format     Abstract available


  110. DUCHESNE L, Lacombe K
    Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings.
    J Viral Hepat. 2017 Nov 13. doi: 10.1111/jvh.12827.
    PubMed     Text format     Abstract available


  111. BHARDWAJ N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, et al
    Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12825.
    PubMed     Text format     Abstract available


  112. SALMON-CERON D, Mondelli MU, Maticic M, Arends JE, et al
    The success of HCV cure: every rose has its thorn.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12823.
    PubMed     Text format     Abstract available


  113. HIKITA H, Sato M, Sato M, Soroida Y, et al
    Disappearance of Perihepatic Lymph Node Enlargement after hepatitis C viral eradication with direct acting antivirals.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12819.
    PubMed     Text format     Abstract available


  114. CANNIZZO ES, Tincati C, Binda F, Ronzi P, et al
    Unconventional T-cells in Chronic Hepatitis B Patients on Long-Term Suppressive Therapy with Tenofovir followed by a Peg-IFN Add-On Strategy: a randomized study.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12820.
    PubMed     Text format     Abstract available


  115. DE ARAUJO NETO JM, Coelho HSM, Chindamo MC, da Motta Rezende GF, et al
    Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12812.
    PubMed     Text format     Abstract available


  116. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Elastogram quality assessment score in Vibration Controlled Transient Elastography: Diagnostic performance compared to digital morphometric analysis of liver biopsy in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12822.
    PubMed     Text format     Abstract available


  117. FOSTER G
    Editorial for "Supplement on Optimal Therapy for Chronic Hepatitis B in China".
    J Viral Hepat. 2017;24 Suppl 1:3.
    PubMed     Text format    


  118. LIU J, Chen T, Zhao Y
    Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment.
    J Viral Hepat. 2017;24 Suppl 1:6-11.
    PubMed     Text format     Abstract available


  119. PAN HY, Pan HY, Song WY, Zheng W, et al
    Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    J Viral Hepat. 2017;24 Suppl 1:29-35.
    PubMed     Text format     Abstract available


  120. LUO XD, Chen XF, Zhou Y, Chen XP, et al
    Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNalpha-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    J Viral Hepat. 2017;24 Suppl 1:36-42.
    PubMed     Text format     Abstract available


  121. YI W, Li MH, Xie Y, Wu J, et al
    Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother-to-child transmission of hepatitis B virus.
    J Viral Hepat. 2017;24 Suppl 1:49-56.
    PubMed     Text format     Abstract available


  122. LI SY, Li H, Xiong YL, Liu F, et al
    Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study.
    J Viral Hepat. 2017;24 Suppl 1:12-20.
    PubMed     Text format     Abstract available


  123. HUANG D, Sansas B, Jiang JH, Gong QM, et al
    Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.
    J Viral Hepat. 2017;24 Suppl 1:66-74.
    PubMed     Text format     Abstract available


  124. SHANG J, Wen Q, Wang CC, Liu K, et al
    Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up.
    J Viral Hepat. 2017;24 Suppl 1:43-48.
    PubMed     Text format     Abstract available


  125. WANG ML, Chen EQ, Zhang DM, Du LY, et al
    Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
    J Viral Hepat. 2017;24 Suppl 1:21-28.
    PubMed     Text format     Abstract available


  126. REN H
    The experience of management of chronic hepatitis B in China.
    J Viral Hepat. 2017;24 Suppl 1:4-5.
    PubMed     Text format     Abstract available


    October 2017
  127. CAMPANA B, Calabrese D, Matter MS, Terracciano LM, et al
    In vivo analysis at the cellular level reveals similar steatosis induction in both HCV genotype 1 and 3 infections.
    J Viral Hepat. 2017 Oct 31. doi: 10.1111/jvh.12816.
    PubMed     Text format     Abstract available


  128. LIANG X, Xie Q, Tan D, Ning Q, et al
    Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12814.
    PubMed     Text format     Abstract available


  129. MA N, Zhang X, Yang L, Zhou J, et al
    Role of Functional IFNL4, IFNLR1, IFNA, IFNAR2 Polymorphisms in Hepatitis B virus-related liver disease in Han Chinese population.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12817.
    PubMed     Text format     Abstract available


  130. CHOI HY, Kim Y, Cho H, Kim BH, et al
    Risk of diabetes in viral hepatitis B or C patients compared to that in non-infected individuals in Korea, 2002-2013: A population-based cohort study.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12815.
    PubMed     Text format     Abstract available


  131. MARCELLIN F, Morlat P, Wittkop L, Salmon-Ceron D, et al
    Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12811.
    PubMed     Text format     Abstract available


  132. OW MM, Hegazy D, Warshow UM, Cramp ME, et al
    Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood.
    J Viral Hepat. 2017 Oct 24. doi: 10.1111/jvh.12810.
    PubMed     Text format     Abstract available


  133. SALUDES V, Folch C, Morales-Carmona A, Ferrer L, et al
    Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona, Spain.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12809.
    PubMed     Text format     Abstract available


  134. YOUNOSSI ZM, Chan HLY, Dan YY, Lee MH, et al
    Impact of Ledipasvir/Sofosbuvir on the Work Productivity of Genotype 1 Chronic Hepatitis C Patients in Asia.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12808.
    PubMed     Text format     Abstract available


  135. NAYLOR PH, Mutchnick MG
    Immunotherapy for Hepatitis B in the Direct Acting Anti-viral Era: Reevaluating the Thymosin alpha1 Efficacy Trials in Light of a Combination Therapy Approach.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12807.
    PubMed     Text format     Abstract available


  136. WEN X, Su H, Wang Y, Pu Z, et al
    Prevalence and natural course of occult hepatitis B virus infection in residents of two communities of Wuwei City, Gansu Province, China.
    J Viral Hepat. 2017 Oct 15. doi: 10.1111/jvh.12805.
    PubMed     Text format     Abstract available


  137. WONG NS, Lee CK, Ng SC, Wong HK, et al
    Prevalence of hepatitis C infection and its associated factors in healthy adults without identifiable route of transmission.
    J Viral Hepat. 2017 Oct 15. doi: 10.1111/jvh.12804.
    PubMed     Text format     Abstract available


  138. MARRONE A, Capoluongo N, D'Amore C, Pisaturo M, et al
    Eighteen-month-lamivudine-prophylaxis on preventing occult hepatitis b virus (hbv) infection reactivation in patients with hematologic malignancies receiving immunosuppression therapy.
    J Viral Hepat. 2017 Oct 13. doi: 10.1111/jvh.12802.
    PubMed     Text format     Abstract available


  139. CAMUS G, Han B, Asselah T, Hsieh D, et al
    Resistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12795.
    PubMed     Text format     Abstract available


  140. TANG L, Parker A, Flores Y, Dellario M, et al
    Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12796.
    PubMed     Text format     Abstract available


  141. NORDMANN S, Vilotitch A, Roux P, Esterle L, et al
    Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH).
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12797.
    PubMed     Text format     Abstract available


  142. SRIDHAR S, Chan JFW, Yap DYH, Teng JLL, et al
    Genotype 4 hepatitis E virus is a cause of chronic hepatitis in renal transplant recipients in Hong Kong.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12799.
    PubMed     Text format     Abstract available


  143. WEIL C, Mehta D, Koren G, Pinsky B, et al
    Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12800.
    PubMed     Text format     Abstract available


  144. CHEN DS, Hamoudi W, Mustapha B, Layden J, et al
    Strategies to manage hepatitis C virus infection disease burden-Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:44-63.
    PubMed     Text format     Abstract available


  145. MAAROUFI A, Vince A, Himatt SM, Mohamed R, et al
    Historical epidemiology of hepatitis C virus in select countries-volume 4.
    J Viral Hepat. 2017;24 Suppl 2:8-24.
    PubMed     Text format     Abstract available


  146. DORE GJ, Hatzakis A, Negro F, Waked I, et al
    Estimating HCV disease burden-volume 4 (editorial).
    J Viral Hepat. 2017;24 Suppl 2:4-7.
    PubMed     Text format     Abstract available


  147. CHAN HLY, Chen CJ, Omede O, Al Qamish J, et al
    The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:25-43.
    PubMed     Text format     Abstract available


    August 2017
  148. SERPER M, Forde KA, Kaplan DE
    Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort.
    J Viral Hepat. 2017 Aug 28. doi: 10.1111/jvh.12784.
    PubMed     Text format     Abstract available


  149. ZHENG H, Cui FQ, Wang FZ, Huang LF, et al
    The epidemiology of hepatitis B virus infection in women of reproductive age in highly endemic areas in China.
    J Viral Hepat. 2017 Aug 23. doi: 10.1111/jvh.12757.
    PubMed     Text format     Abstract available


  150. SHAFRAN SD, Shaw D, Charafeddine M, Agarwal K, et al
    Efficacy and Safety Results of Patients with HCV Genotype 2 or 3 Infection Treated with Ombitasvir/Paritaprevir/ritonavir and Sofosbuvir with or without Ribavirin (QUARTZ II-III).
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12782.
    PubMed     Text format     Abstract available


  151. KITRINOS KM, Corsa AC, Worth A, Hedskog C, et al
    Nonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir.
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12783.
    PubMed     Text format     Abstract available


  152. KRAMER JR, El-Serag HB, Taylor TJ, White DL, et al
    Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
    J Viral Hepat. 2017 Aug 16. doi: 10.1111/jvh.12728.
    PubMed     Text format     Abstract available


  153. BARONE M, Iannone A, Shahini E, Ippolito AM, et al
    A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: the ITAL-C network study.
    J Viral Hepat. 2017 Aug 8. doi: 10.1111/jvh.12765.
    PubMed     Text format     Abstract available


  154. MERCHANTE N, Aldamiz-Echevarria T, Garcia-Alvarez M, Rivero-Juarez A, et al
    Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12769.
    PubMed     Text format     Abstract available


  155. VON FELDEN J, Scheurich C, Yamamura J, Brainard DM, et al
    Successful treatment of chronic hepatitis C with ground ledipasvir / sofosbuvir in a patient with Crohn's disease and short bowel syndrome.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12768.
    PubMed     Text format     Abstract available


  156. FOURNIER C, Hoffmann TW, Morel V, Descamps V, et al
    Claudin-1, miR-122 and Apolipoprotein E transduction improves the permissivity of SNU-182, SNU-398 and SNU-449 Hepatoma cells to Hepatitis C Virus.
    J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12767.
    PubMed     Text format     Abstract available


  157. HUI RW, Seto WK, Cheung KS, Mak LY, et al
    Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case control study.
    J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12766.
    PubMed     Text format     Abstract available


    July 2017
  158. HALLAGER S, Ladelund S, Kjaer MS, Madsen LG, et al
    Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study.
    J Viral Hepat. 2017 Jul 27. doi: 10.1111/jvh.12764.
    PubMed     Text format     Abstract available


  159. JACKA B, Bray B, Applegate TL, Marshall BD, et al
    Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12758.
    PubMed     Text format     Abstract available


  160. SOLOMON SS, Sulkowski MS, Amrose P, Srikrishnan AK, et al
    Directly Observed Therapy of Sofosbuvir/Ribavirin +/- Peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12761.
    PubMed     Text format     Abstract available


  161. CHAKRABARTY G, Bruce M, Horner M, Wang B, et al
    Can Quantitative Hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
    J Viral Hepat. 2017 Jul 14. doi: 10.1111/jvh.12756.
    PubMed     Text format     Abstract available


  162. CALVARUSO V, Ferraro D, Licata A, Bavetta MG, et al
    HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct acting antivirals.
    J Viral Hepat. 2017 Jul 13. doi: 10.1111/jvh.12754.
    PubMed     Text format     Abstract available


  163. GARDNER SD, Kim J, Baptiste-Brown S, Lopez V, et al
    GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naive chronic hepatitis C subjects.
    J Viral Hepat. 2017 Jul 10. doi: 10.1111/jvh.12753.
    PubMed     Text format     Abstract available


  164. AL-QAHTANI AA, Al-Anazi MR, Nazir N, Wani K, et al
    Association of Single Nucleotide Polymorphisms in MicroRNAs with Susceptibility to Hepatitis B Virus Infection and HBV-related Liver Complications: A Study in a Saudi Arabian Population.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12749.
    PubMed     Text format     Abstract available


  165. SALAZAR-VIZCAYA L, Kouyos RD, Fehr J, Braun D, et al
    On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12752.
    PubMed     Text format     Abstract available


  166. LI Q, Lu C, Li W, Huang Y, et al
    The gamma-glutamyl transpeptidase to albumin ratio predicts significant fibrosis and cirrhosis in chronic hepatitis B patients.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12751.
    PubMed     Text format     Abstract available


    June 2017
  167. BENOVA L, Awad SF, Abu-Raddad LJ
    Estimate of vertical transmission of Hepatitis C virus in Pakistan in 2007 and 2012 birth cohorts.
    J Viral Hepat. 2017 Jun 29. doi: 10.1111/jvh.12748.
    PubMed     Text format     Abstract available


  168. LI Y, Li Y, Zhang L, Li W, et al
    Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies.
    J Viral Hepat. 2017 Jun 28. doi: 10.1111/jvh.12742.
    PubMed     Text format     Abstract available


  169. SIDDIQUI ZI, Farooqui SR, Azam SA, Afroz M, et al
    A comparative study of hepatitis B virus X protein mutants K130M, V131I and KV130/131MI to investigate their roles in fibrosis, cirrhosis and hepatocellular carcinoma.
    J Viral Hepat. 2017 Jun 27. doi: 10.1111/jvh.12747.
    PubMed     Text format     Abstract available


  170. TENG W, Hsieh YC, Lui KW, Chen WT, et al
    Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12745.
    PubMed     Text format     Abstract available


  171. SCHIAVINATO A, Zanetto A, Pantano G, Tosato F, et al
    Polyclonal and monoclonal B-lymphocytes response in HCV patients treated with direct-acting antiviral agents.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12746.
    PubMed     Text format     Abstract available


  172. DE LA TORRE AN, Castaneda I, Ahmad M, Ekholy N, et al
    Audio Computer Assisted Survey Interview and Patient Navigation to Increase Chronic Viral Hepatitis Diagnosis and Linkage to Care in Urban Health Clinics.
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12744.
    PubMed     Text format     Abstract available


  173. DIRKS M, Pflugrad H, Weissenborn K
    Response to letter to the editor: Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12740.
    PubMed     Text format     Abstract available


  174. YANG R, Gui X, Xiong Y, Gao S, et al
    Long-term Follow-up of Patients Triply Infected with HIV and Hepatitis B and C Viruses in a Comprehensive Hospital in Central China.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12739.
    PubMed     Text format     Abstract available


  175. GADE A
    Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12743.
    PubMed     Text format     Abstract available


  176. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12737.
    PubMed     Text format     Abstract available


  177. STELMA F, van der Ree MH, Jansen L, Peters MW, et al
    HBsAg loss after peginterferon and nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12738.
    PubMed     Text format     Abstract available


  178. JOHNSON K, Green PK, Ioannou GN
    Implications of HCV RNA level at week 4 of direct antiviral treatments for Hepatitis C.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12731.
    PubMed     Text format     Abstract available


  179. WONG RJ, Nguyen MT, Trinh HN, Chan C, et al
    Hepatitis B Surface Antigen Loss and Sustained Viral Suppression in Asian Chronic Hepatitis B Patients: A Community-Based Real World Study.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12736.
    PubMed     Text format     Abstract available


  180. KIM HS, Rotundo L, Yang JD, Kim D, et al
    Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12735.
    PubMed     Text format     Abstract available


  181. EL SHERIF O, Afhdal N, Curry M
    No one size fits all - shortening duration of therapy with direct acting antivirals for Hepatitis C genotype 1 infection.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12734.
    PubMed     Text format     Abstract available


  182. NING L, Lin W, Hu X, Rong F, et al
    Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12733.
    PubMed     Text format     Abstract available


  183. LOK AS, Ganova-Raeva L, Cloonan Y, Punkova L, et al
    Prevalence of Hepatitis B Antiviral Drug Resistance Variants in North American Patients with Chronic Hepatitis B Not Receiving Antiviral Treatment.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12732.
    PubMed     Text format     Abstract available


  184. SHARMA S, Kumar A, Kar P, Agarwal S, et al
    Risk factors for vertical transmssion of hepatitis E virus infection.
    J Viral Hepat. 2017 Jun 1. doi: 10.1111/jvh.12730.
    PubMed     Text format     Abstract available


  185. HAN GR, Jiang HX, Wang CM, Ding Y, et al
    Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy.
    J Viral Hepat. 2017;24:514-521.
    PubMed     Text format     Abstract available


    May 2017
  186. BROUWER WP, van der Meer AJ, Boonstra A, Plompen EPC, et al
    Prediction of long-term clinical outcome in a diverse chronic hepatitis b population: role of the PAGE-B score.
    J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12727.
    PubMed     Text format     Abstract available


  187. FITCH DN, Dharod A, Campos CL, Nunez M, et al
    Use of Electronic Health Record Clinical Decision Support Tool for HCV Birth Cohort Screening.
    J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12729.
    PubMed     Text format     Abstract available


  188. ROB B, Moreno C, Van Vlierberghe H, Bourgeois S, et al
    The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon: A Belgian experience.
    J Viral Hepat. 2017 May 15. doi: 10.1111/jvh.12726.
    PubMed     Text format     Abstract available


  189. OSIBOGUN O, Ogunmoroti O, Michos ED, Spatz ES, et al
    HIV/HCV Co-infection and the risk of Cardiovascular Disease: A Meta-analysis.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12725.
    PubMed     Text format     Abstract available


  190. MCLEOD A, Cullen BL, Hutchinson SJ, Roy KM, et al
    Limited Impact of Awareness-Raising Campaigns on Hepatitis C Testing Practices among General Practitioners.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12724.
    PubMed     Text format     Abstract available


  191. KIM GA, Han S, Kim HD, An J, et al
    Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis B vs Chronic Hepatitis C after Achievement of Virologic Response.
    J Viral Hepat. 2017 May 12. doi: 10.1111/jvh.12723.
    PubMed     Text format     Abstract available


  192. WEDEMEYER H, Craxi A, Zuckerman E, Dieterich D, et al
    Real-World Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in Patients with HCV Genotype 1 or 4 Infection: a Meta-Analysis.
    J Viral Hepat. 2017 May 8. doi: 10.1111/jvh.12722.
    PubMed     Text format     Abstract available


  193. SHAWA IT, Felmlee DJ, Hegazy D, Sheridan DA, et al
    Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12720.
    PubMed     Text format     Abstract available


  194. HLAING NKT, Mitrani RA, Aung ST, Phyo WW, et al
    Safety and Efficacy of Sofosbuvir-Based DAA Regimens for Hepatitis C Virus Genotypes 1 - 4 and 6 in Myanmar: Real-world experience.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12721.
    PubMed     Text format     Abstract available


  195. GANE E, Nahass R, Luketic V, Asante-Appiah E, et al
    Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, non-cirrhotic HCV genotype 3-infected patients.
    J Viral Hepat. 2017 May 4. doi: 10.1111/jvh.12719.
    PubMed     Text format     Abstract available


    April 2017
  196. STEININGER K, Boyd A, Dupke S, Krznaric I, et al
    HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    J Viral Hepat. 2017 Apr 25. doi: 10.1111/jvh.12707.
    PubMed     Text format     Abstract available


  197. LAARIBI AB, Bortolotti D, Hannachi N, Mehri A, et al
    Increased levels of soluble HLA-G molecules in Tunisian patients with chronic hepatitis B infection.
    J Viral Hepat. 2017 Apr 21. doi: 10.1111/jvh.12718.
    PubMed     Text format     Abstract available


  198. CAI YJ, Dong JJ, Wang XD, Huang SS, et al
    A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12715.
    PubMed     Text format     Abstract available


  199. PAPASAVVAS E, Azzoni L, Yin X, Liu Q, et al
    HCV viremia associates with NK cell activation and dysfunction in anti retroviral HIV/HCV co-infected subjects.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12714.
    PubMed     Text format     Abstract available


  200. DE GROEN RA, Groothuismink ZMA, van Oord G, Kootstra NA, et al
    NK cells in self-limited HCV infection exhibit a more extensively differentiated, but not memory-like, repertoire.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12716.
    PubMed     Text format     Abstract available


  201. MGAIETH S, Kemp W, Gow P, Fink M, et al
    Impact of viral hepatitis etiology on survival outcomes in hepatocellular carcinoma: a large multi-center cohort study.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12717.
    PubMed     Text format     Abstract available


  202. HUANG CE, Yang YH, Chen YY, Chang JJ, et al
    The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma.
    J Viral Hepat. 2017 Apr 4. doi: 10.1111/jvh.12713.
    PubMed     Text format     Abstract available


    March 2017
  203. VUKOTIC R, Conti F, Fagiuoli S, Morelli MC, et al
    Long-term outcomes of DAAs in post-transplant advanced HCV recurrence and fibrosing cholestatic hepatitis.
    J Viral Hepat. 2017 Mar 28. doi: 10.1111/jvh.12712.
    PubMed     Text format     Abstract available


  204. BOGLIONE L, Mornese Pinna S, De Nicolo A, Cusato J, et al
    Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study.
    J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12711.
    PubMed     Text format     Abstract available


  205. XU JH, Wang S, Xu ZN, Yu YY, et al
    Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: results at week 144.
    J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12710.
    PubMed     Text format     Abstract available


  206. SU H, Shao Z, Pu Z, Wang Y, et al
    Overt and occult hepatitis B virus infection among community children in Northwest China.
    J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12709.
    PubMed     Text format     Abstract available


  207. WELZEL TM, Hinrichsen H, Sarrazin C, Buggisch P, et al
    Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
    J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12708.
    PubMed     Text format     Abstract available


  208. AFDHAL N, Everson GT, Calleja JL, McCaughan GW, et al
    Effect of Viral Suppression on Hepatic Venous Pressure Gradient in Hepatitis C With Cirrhosis and Portal Hypertension.
    J Viral Hepat. 2017 Mar 10. doi: 10.1111/jvh.12706.
    PubMed     Text format     Abstract available


  209. BUTI M, Dominguez-Hernandez R, Oyaguez I, Casado MA, et al
    Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12704.
    PubMed     Text format     Abstract available


  210. YOUNG K, Liu B, Bhuket T, Younossi Z, et al
    Long Term Trends in Chronic Hepatitis B Virus Infection Associated Liver Transplantation Outcomes in the United States.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12703.
    PubMed     Text format     Abstract available


  211. CHEW KW, Bhattacharya D, Horwich TB, Yan P, et al
    Performance of the Pooled Cohort Atherosclerotic Cardiovascular Disease Risk Score in Hepatitis C Virus-infected Persons.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12705.
    PubMed     Text format     Abstract available


  212. SHRIVASTAVA S, Wilson E, Poonia B, Tang L, et al
    Augmentation of HCV specific immunity and Sustained virological response (SVR).
    J Viral Hepat. 2017 Mar 7. doi: 10.1111/jvh.12702.
    PubMed     Text format     Abstract available


  213. CUNNINGHAM EB, Harjarizadeh B, Bretana NA, Amin J, et al
    Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study.
    J Viral Hepat. 2017 Mar 3. doi: 10.1111/jvh.12701.
    PubMed     Text format     Abstract available


  214. SMITH HL, Chung RT, Mantry P, Chapman W, et al
    Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
    J Viral Hepat. 2017;24:197-206.
    PubMed     Text format     Abstract available


  215. TAIT JM, Wang H, Stephens BP, Miller M, et al
    Multidisciplinary managed care networks-Life-saving interventions for hepatitis C patients.
    J Viral Hepat. 2017;24:207-215.
    PubMed     Text format     Abstract available


  216. AGUILERA A, Navarro D, Rodriguez Frias F, Viciana I, et al
    Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (The GEHEP 005 study).
    J Viral Hepat. 2017 Mar 1. doi: 10.1111/jvh.12700.
    PubMed     Text format     Abstract available


    February 2017
  217. ROMANI S, Hosseini SM, Mohebbi SR, Boonstra A, et al
    Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection.
    J Viral Hepat. 2017 Feb 20. doi: 10.1111/jvh.12699.
    PubMed     Text format     Abstract available


  218. DASHTSEREN B, Bungert A, Bat-Ulzii P, Enkhbat M, et al
    Endemic prevalence of hepatitis B and C in Mongolia: A nationwide survey among Mongolian adults.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12697.
    PubMed     Text format     Abstract available


  219. SHAKER OG, Senousy MA
    Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12696.
    PubMed     Text format     Abstract available


  220. DI BONA D, Aiello A, Colomba C, Bilancia M, et al
    KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12698.
    PubMed     Text format     Abstract available


  221. ZHANG W, Xie Q, Ning Q, Dou X, et al
    The role of peginterferon in nucleos(t)ide-analogue-treated chronic hepatitis B patients: a review of published literature.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12695.
    PubMed     Text format     Abstract available


  222. GRANNAN S
    Understanding Patient Perceptions and Risk for Hepatitis C Screening.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12692.
    PubMed     Text format     Abstract available


  223. YONGHAO G, Pumei D, Jianhui Y, Jin X, et al
    A retrospective study of hepatitis B mother-to-child transmission prevention and post-vaccination serological test results of infants at risk of perinatal transmission in two counties of middle China.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12694.
    PubMed     Text format     Abstract available


  224. TAMAKI N, Kurosaki M, Kusakabe A, Orito E, et al
    Hepatitis B Surface Antigen Reduction by Switching from Long-term Nucleoside/nucleotide Analog Administration to Pegylated Interferon.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12691.
    PubMed     Text format     Abstract available


  225. SOOMRO MH, Shi R, She R, Yang Y, et al
    Molecular and structural changes related to Hepatitis E virus (HEV) antigen and its expression in testis inducing apoptosis in Mongolian gerbil model.
    J Viral Hepat. 2017 Feb 9. doi: 10.1111/jvh.12690.
    PubMed     Text format     Abstract available


  226. HSU HY, Chang MH, Ni YH, Chiang CL, et al
    Chronologic changes of serum hepatitis B virus DNA, genotypes, surface antigen mutants and reverse transcriptase mutants during 25-year nationwide immunization in Taiwan.
    J Viral Hepat. 2017 Feb 9. doi: 10.1111/jvh.12687.
    PubMed     Text format     Abstract available


  227. MEIER MA, Suslov A, Ketterer S, Heim MH, et al
    Hepatitis B Virus covalently closed circular DNA homeostasis is independent of the lymphotoxin pathway during chronic HBV infection.
    J Viral Hepat. 2017 Feb 9. doi: 10.1111/jvh.12689.
    PubMed     Text format     Abstract available


  228. INGILIZ P
    Martinello et al.,HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2017 Feb 7. doi: 10.1111/jvh.12686.
    PubMed     Text format     Abstract available


  229. EL-AKEL W, El-Sayed MH, El Kassas M, El-Serafy M, et al
    National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care.
    J Viral Hepat. 2017 Feb 1. doi: 10.1111/jvh.12668.
    PubMed     Text format     Abstract available


    January 2017
  230. ZHU MY, Zou X, Li Q, Yu DM, et al
    A novel noninvasive algorithm for the assessment of liver fibrosis in patients with chronic hepatitis B virus infection.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12682.
    PubMed     Text format     Abstract available


  231. HUNG CH, Wang JH, Lu SN, Hu TH, et al
    Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analog therapy.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12683.
    PubMed     Text format     Abstract available


  232. JANJUA NZ, Islam N, Wong J, Yoshida EM, et al
    Shift in disparities in Hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12684.
    PubMed     Text format     Abstract available


  233. DIRKS M, Pflugrad H, Haag K, Tillmann HL, et al
    Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?!
    J Viral Hepat. 2017 Jan 24. doi: 10.1111/jvh.12674.
    PubMed     Text format     Abstract available


  234. CHEN J, Xu CR, Xi M, Hu WW, et al
    Predictors of liver histological changes and a sustained response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12679.
    PubMed     Text format     Abstract available


  235. YU F, Zhou G, Huang K, Fan X, et al
    Serum lincRNA-p21 as a potential biomarker of liver fibrosis in chronic hepatitis B patients.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12680.
    PubMed     Text format     Abstract available


  236. MENDIZABAL M, Reddy KR
    Chronic Hepatitis C and Chronic Kidney disease: Advances, Limitations and Unchartered Territories.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12681.
    PubMed     Text format     Abstract available


  237. FERNANDEZ-PONCE C, Munoz-Miranda JP, Arbulo-Echevarria MM, Litran R, et al
    Immune modulation by the Hepatitis C virus core protein.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12675.
    PubMed     Text format     Abstract available


  238. VEDIO A, Liu EZ, Lee AC, Salway S, et al
    Improving access to health care for chronic hepatitis B among migrant Chinese populations: a systematic mixed methods review of barriers and enablers.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12673.
    PubMed     Text format     Abstract available


  239. PLUMB ID, Bulkow LR, Bruce MG, Hennessy TW, et al
    Persistence of Antibody to Hepatitis A Virus 20 Years After Receipt of Hepatitis A Vaccine in Alaska.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12676.
    PubMed     Text format     Abstract available


  240. ZHOU S, Cella E, Zhou W, Kong WH, et al
    Population dynamics of HCV subtypes in injecting drug-users on methadone maintenance treatment in China associated with economic and health reform.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12677.
    PubMed     Text format     Abstract available


  241. LIU Z, Jiang L, Liang G, Song E, et al
    Hepatitis B Virus Reactivation in Breast Cancer Patients Undergoing Chemotherapy: a review and meta-analysis of prophylaxis management.
    J Viral Hepat. 2017 Jan 10. doi: 10.1111/jvh.12672.
    PubMed     Text format     Abstract available


  242. VUKOTIC R, Di Donato R, Conti F, Scuteri A, et al
    Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.
    J Viral Hepat. 2017;24:13-16.
    PubMed     Text format     Abstract available


  243. LI X, Gou C, Yao L, Lei Z, et al
    Patients with HBV-related acute-on-chronic liver failure have increased concentrations of extracellular histones aggravating cellular damage and systemic inflammation.
    J Viral Hepat. 2017;24:59-67.
    PubMed     Text format     Abstract available


    December 2016
  244. GOEL A, Sanchez J, Paulino L, Feuille C, et al
    A systematic model improves hepatitis C virus birth cohort screening in hospital-based primary care.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12669.
    PubMed     Text format     Abstract available


  245. AYOUB H, Abu-Raddad LJ
    Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12671.
    PubMed     Text format     Abstract available


  246. MARTINELLO M, Grebely J, Petoumenos K, Gane E, et al
    HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2016 Dec 27. doi: 10.1111/jvh.12666.
    PubMed     Text format     Abstract available


  247. PAN CQ, Yi W, Liu M, Wan G, et al
    Lamivudine therapy during the second vs the third trimester for preventing transmission of chronic hepatitis B.
    J Viral Hepat. 2016 Dec 26. doi: 10.1111/jvh.12640.
    PubMed     Text format     Abstract available


  248. THARINGER H, Rebbapragada I, Samuel D, Novikov N, et al
    Antibody-dependent and -independent uptake of HBsAg across human leukocyte subsets is similar between individuals with chronic hepatitis B Virus infection and healthy donors.
    J Viral Hepat. 2016 Dec 23. doi: 10.1111/jvh.12667.
    PubMed     Text format     Abstract available


  249. TOYODA H, Tada T, Takaguchi K, Senoh T, et al
    Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepa
    J Viral Hepat. 2016 Dec 16. doi: 10.1111/jvh.12665.
    PubMed     Text format     Abstract available


  250. PERELLO C, Carrion JA, Ruiz-Antoran B, Crespo J, et al
    Effectiveness and safety of ombitasvir, paritaprevir, ritonavir +/- dasabuvir +/- ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12637.
    PubMed     Text format     Abstract available


  251. MUNOZ-GOMEZ R, Rincon D, Ahumada A, Hernandez E, et al
    Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotype 1 and 4 hepatitis C virus infection (HCV) in patients with severe renal impairment: a multicenter experience.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12664.
    PubMed     Text format     Abstract available


  252. CONTI F, Brillanti S, Buonfiglioli F, Vukotic R, et al
    Safety and efficacy of direct acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12663.
    PubMed     Text format     Abstract available


  253. ELBASHA E, Greaves W, Roth D, Nwankwo C, et al
    Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    J Viral Hepat. 2016 Dec 13. doi: 10.1111/jvh.12639.
    PubMed     Text format     Abstract available


  254. XIONG H, Rong X, Wang M, Xu R, et al
    HBV/HCV co-infection is associated with a high level of HCV spontaneous clearance among drug users and blood donors in China.
    J Viral Hepat. 2016 Dec 12. doi: 10.1111/jvh.12644.
    PubMed     Text format     Abstract available


  255. ALONSO S, Riveiro-Barciela M, Fernandez I, Rincon D, et al
    Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12648.
    PubMed     Text format     Abstract available


  256. ALQAHTANI S, Ozaras R, Isakov V, Wyles D, et al
    Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12641.
    PubMed     Text format     Abstract available


  257. SHAH SR, Chowdhury A, Mehta R, Kapoor D, et al
    Sofosbuvir plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12654.
    PubMed     Text format     Abstract available


  258. DING Y, Duan S, Ye R, Yang Y, et al
    More Improvement than Progression of Liver Fibrosis Following Antiretroviral Therapy in A Longitudinal Cohort of HIV-infected Patients With or Without HBV and HCV Co-infections.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12658.
    PubMed     Text format     Abstract available


  259. GIMENO-BALLESTER V, Buti M, San Miguel R, Riveiro M, et al
    Interferon-free therapies for Patients with Chronic Hepatitis C Genotype 3 Infection: A Systematic Review.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12660.
    PubMed     Text format     Abstract available


  260. GITTO S, Gamal N, Andreone P
    NS5A inhibitors for the treatment of hepatitis C infection.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12657.
    PubMed     Text format     Abstract available


  261. WARING JF, Davis JW, Dumas E, Cohen D, et al
    Epigenetic analysis of the IFNlambda3 gene identifies a novel marker for response to therapy in HCV-infected subjects.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12661.
    PubMed     Text format     Abstract available


  262. CHANG LY, Li Y, Kaplan DE
    Hepatitis C viremia reversibly maintains subset of antigen-specific T-bet+ tissue-like memory B-cells.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12659.
    PubMed     Text format     Abstract available


  263. ALAEI A, Alaei K, Waye K, Tracy M, et al
    Hepatitis C Infection and Other Drug Related Harms Among Inpatients Who Injected Drugs in Turkey.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12662.
    PubMed     Text format     Abstract available


  264. DI BISCEGLIE AM, Lombardero M, Teckman J, Roberts L, et al
    Determination of hepatitis B phenotype using biochemical and serological markers.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12643.
    PubMed     Text format     Abstract available


  265. DURIER N, Yunihastuti E, Ruxrungtham K, Kinh NV, et al
    Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12630.
    PubMed     Text format     Abstract available


  266. KANAAN N, Raggi C, Goffin E, De Meyer M, et al
    Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12655.
    PubMed     Text format     Abstract available


  267. EMMANUEL B, Shardell MD, Tracy L, Kottilil S, et al
    Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12656.
    PubMed     Text format     Abstract available


  268. LLANERAS J, Riveiro-Barciela M, Buti M, Esteban R, et al
    Hepatitis C virus genotype 4: Genotype 1's little brother.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12620.
    PubMed     Text format     Abstract available


    November 2016
  269. LIU Y, Tang K, Long J, Zhao C, et al
    The association between hepatitis B self-awareness and depression: Exploring the modifying effects of socio-economic factors.
    J Viral Hepat. 2016 Nov 28. doi: 10.1111/jvh.12647.
    PubMed     Text format     Abstract available


  270. XU JH, Song LW, Li N, Wang S, et al
    Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir.
    J Viral Hepat. 2016 Nov 28. doi: 10.1111/jvh.12626.
    PubMed     Text format     Abstract available


  271. ISLAM N, Krajden M, Gilbert M, Gustafson P, et al
    Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: The BC Hepatitis Testers Cohort.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12650.
    PubMed     Text format     Abstract available


  272. MCDONALD SA, Innes HA, Aspinall E, Hayes PC, et al
    Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12646.
    PubMed     Text format     Abstract available


  273. CHUAI X, Chen P, Chen H, Wang W, et al
    Protective efficacy and hepatitis B virus clearance in mice enhanced by cell-mediated immunity with novel prime-boost regimens.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12649.
    PubMed     Text format     Abstract available


  274. BARTLETT SR, Wertheim JO, Bull RA, Matthews GV, et al
    A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.
    J Viral Hepat. 2016 Nov 24. doi: 10.1111/jvh.12652.
    PubMed     Text format     Abstract available


  275. LAWITZ E, Poordad F, Gutierrez JA, Kakuda TN, et al
    Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
    J Viral Hepat. 2016 Nov 23. doi: 10.1111/jvh.12645.
    PubMed     Text format     Abstract available


  276. JOO EJ, Chang Y, Yeom JS, Lee YG, et al
    Hepatitis B infection is associated with an increased incidence of thrombocytopenia in healthy adults without cirrhosis.
    J Viral Hepat. 2016 Nov 18. doi: 10.1111/jvh.12642.
    PubMed     Text format     Abstract available


  277. CHEN RC, Cai YJ, Wu JM, Wang XD, et al
    Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis.
    J Viral Hepat. 2016 Nov 14. doi: 10.1111/jvh.12638.
    PubMed     Text format     Abstract available


  278. BRUNO G, Saracino A, Fabrizio C, Scudeller L, et al
    Rapid improvement in liver fibrosis in HCV-infected patients with or without HIV infection and DAA-induced SVR: A "turning-off" effect of liver inflammation?
    J Viral Hepat. 2016 Nov 14. doi: 10.1111/jvh.12636.
    PubMed     Text format    


  279. HEZODE C
    Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.
    J Viral Hepat. 2016 Nov 9. doi: 10.1111/jvh.12635.
    PubMed     Text format     Abstract available


  280. KHARABIAN MASOULEH S, Herzig S, Klose L, Roggenhofer E, et al
    Functional connectivity alterations in patients with chronic hepatitis C virus infection: A multimodal MRI study.
    J Viral Hepat. 2016 Nov 4. doi: 10.1111/jvh.12634.
    PubMed     Text format     Abstract available


  281. HUNDIE GB, Stalin Raj V, Gebre Michael D, Pas SD, et al
    A novel hepatitis B virus subgenotype D10 circulating in Ethiopia.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12631.
    PubMed     Text format     Abstract available


  282. RODRIGO C, Eltahla AA, Bull RA, Luciani F, et al
    Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12616.
    PubMed     Text format     Abstract available


  283. ITO H, Ando T, Nakamura M, Ishida H, et al
    Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12629.
    PubMed     Text format     Abstract available


  284. THOMPSON AJ, Bowden DS
    Vidal LL, et al. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct HCV genotypes from worldwide treatment-naive subjects. JVH, 2016, 23(11): 840-849.
    J Viral Hepat. 2016;23:838-839.
    PubMed     Text format    


    October 2016
  285. ESMAEILI A, Mirzazadeh A, Carter GM, Esmaeili A, et al
    Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis.
    J Viral Hepat. 2016 Oct 28. doi: 10.1111/jvh.12628.
    PubMed     Text format     Abstract available


  286. EL RAZIKY M, Gamil M, Ashour MK, Sameea EA, et al
    Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naive and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
    J Viral Hepat. 2016 Oct 27. doi: 10.1111/jvh.12625.
    PubMed     Text format     Abstract available


  287. LAFFERTY L, Treloar C, Guthrie J, Chambers GM, et al
    Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison.
    J Viral Hepat. 2016 Oct 24. doi: 10.1111/jvh.12627.
    PubMed     Text format     Abstract available


  288. LEE S, Ahn SH, Jung KS, Kim DY, et al
    Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
    J Viral Hepat. 2016 Oct 20. doi: 10.1111/jvh.12623.
    PubMed     Text format     Abstract available


  289. TAPPER EB, Bacon BR, Curry MP, Dieterich DT, et al
    Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
    J Viral Hepat. 2016 Oct 11. doi: 10.1111/jvh.12611.
    PubMed     Text format     Abstract available


  290. CRISAN D, Radu C, Suciu A, Leach N, et al
    Hepatitis C in nonobese nondiabetic patients: Insulin resistance and the metabolic syndrome make a difference.
    J Viral Hepat. 2016 Oct 4. doi: 10.1111/jvh.12610.
    PubMed     Text format    


  291. SCHEMMERER M, Rauh C, Jilg W, Wenzel JJ, et al
    Time course of hepatitis E-specific antibodies in adults.
    J Viral Hepat. 2016 Oct 4. doi: 10.1111/jvh.12621.
    PubMed     Text format     Abstract available


  292. FEVERY B, Verbinnen T, Peeters M, Janssen K, et al
    Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
    J Viral Hepat. 2016 Oct 3. doi: 10.1111/jvh.12614.
    PubMed     Text format     Abstract available


    September 2016
  293. SHI KQ, Zhou YY, Yan HD, Li H, et al
    Classification and regression tree analysis of acute-on-chronic hepatitis B liver failure: Seeing the forest for the trees.
    J Viral Hepat. 2016 Sep 30. doi: 10.1111/jvh.12617.
    PubMed     Text format     Abstract available


  294. WONG RJ, Nguyen MT, Trinh HN, Huynh A, et al
    Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.
    J Viral Hepat. 2016 Sep 27. doi: 10.1111/jvh.12609.
    PubMed     Text format     Abstract available


  295. EMMANUEL B, Sidique N, Zhang X, Poonia B, et al
    Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12618.
    PubMed     Text format     Abstract available


  296. ELTAHLA AA, Rodrigo C, Betz-Stablein B, Grebely J, et al
    Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12615.
    PubMed     Text format     Abstract available


  297. LIU Y, Corsa AC, Buti M, Cathcart AL, et al
    No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    J Viral Hepat. 2016 Sep 23. doi: 10.1111/jvh.12613.
    PubMed     Text format     Abstract available


  298. TRIGO C, do Brasil PE, Costa MJ, de Castro L, et al
    Occult hepatitis B virus infection: clinical implications in tuberculosis treatment.
    J Viral Hepat. 2016 Sep 13. doi: 10.1111/jvh.12583.
    PubMed     Text format     Abstract available


  299. EL-BENDARY M, Neamatallah M, Esmat G, Kamel E, et al
    Associations of human leucocyte antigen class II-DQB1 alleles with hepatitis C virus infection in Egyptian population: a multicentre family-based study.
    J Viral Hepat. 2016 Sep 7. doi: 10.1111/jvh.12573.
    PubMed     Text format     Abstract available


    August 2016
  300. KEOSHKERIAN E, Hunter M, Cameron B, Nguyen N, et al
    Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection.
    J Viral Hepat. 2016 Aug 25. doi: 10.1111/jvh.12576.
    PubMed     Text format     Abstract available


  301. PRABDIAL-SING N, Chirwa T, Thaver J, Smuts H, et al
    Hepatitis C genotype distribution in patient and blood donor samples in South Africa for the period 2008-2012.
    J Viral Hepat. 2016 Aug 21. doi: 10.1111/jvh.12571.
    PubMed     Text format     Abstract available


  302. ASPINALL EJ, Mitchell W, Schofield J, Cairns A, et al
    A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy.
    J Viral Hepat. 2016 Aug 11. doi: 10.1111/jvh.12580.
    PubMed     Text format     Abstract available


  303. ALLARD N, Dev A, Dwyer J, Srivatsa G, et al
    Factors associated with poor adherence to antiviral treatment for hepatitis B.
    J Viral Hepat. 2016 Aug 9. doi: 10.1111/jvh.12582.
    PubMed     Text format     Abstract available


  304. BRAHMANIA M, Brouwer WP, Hansen T, Mazzulli T, et al
    Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
    J Viral Hepat. 2016 Aug 9. doi: 10.1111/jvh.12579.
    PubMed     Text format     Abstract available


  305. KNOP V, Hoppe D, Welzel T, Vermehren J, et al
    Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.
    J Viral Hepat. 2016 Aug 8. doi: 10.1111/jvh.12578.
    PubMed     Text format     Abstract available


  306. BOYD A, Piroth L, Maylin S, Maynard-Muet M, et al
    Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.
    J Viral Hepat. 2016 Aug 3. doi: 10.1111/jvh.12581.
    PubMed     Text format     Abstract available


    July 2016
  307. NISHIKAWA H, Enomoto H, Iwata Y, Kishino K, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study.
    J Viral Hepat. 2016 Jul 31. doi: 10.1111/jvh.12575.
    PubMed     Text format     Abstract available


  308. CHEN X, Gui X, Zhang L, Huang F, et al
    Maternal anti-HBVs suppress the immune response of infants to hepatitis B vaccine.
    J Viral Hepat. 2016 Jul 29. doi: 10.1111/jvh.12572.
    PubMed     Text format     Abstract available


  309. WANG X, Gao F, Yuan G, Shi K, et al
    Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-alpha and ribavirin therapy.
    J Viral Hepat. 2016 Jul 24. doi: 10.1111/jvh.12574.
    PubMed     Text format     Abstract available


  310. SWANN RE, Mandalou P, Robinson MW, Ow MM, et al
    Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.
    J Viral Hepat. 2016 Jul 13. doi: 10.1111/jvh.12568.
    PubMed     Text format     Abstract available


  311. WILLEMSE SB, Baak LC, Kuiken SD, van der Sluys Veer A, et al
    Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
    J Viral Hepat. 2016 Jul 13. doi: 10.1111/jvh.12567.
    PubMed     Text format     Abstract available


  312. CHEN CM, Chen SC, Yang HY, Yang ST, et al
    Hospitalization and mortality due to hepatitis A in Taiwan: a 15-year nationwide cohort study.
    J Viral Hepat. 2016 Jul 7. doi: 10.1111/jvh.12564.
    PubMed     Text format     Abstract available


  313. MARTINOT-PEIGNOUX M, Lapalus M, Maylin S, Boyer N, et al
    Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.
    J Viral Hepat. 2016 Jul 4. doi: 10.1111/jvh.12565.
    PubMed     Text format     Abstract available


    June 2016
  314. GHOSH S, Sow A, Guillot C, Jeng A, et al
    Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries.
    J Viral Hepat. 2016 Jun 29. doi: 10.1111/jvh.12561.
    PubMed     Text format     Abstract available


  315. SCHEURICH C, Schulze Zur Wiesch J, Kim AY, Lewis-Ximenez L, et al
    Breadth of the HCV-specific CD4+ T-cell response in spontaneous resolvers is independent of the IL-28 haplotype.
    J Viral Hepat. 2016 Jun 27. doi: 10.1111/jvh.12560.
    PubMed     Text format    


  316. KAWAKAMI Y, Imamura M, Ikeda H, Suzuki M, et al
    Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study.
    J Viral Hepat. 2016 Jun 27. doi: 10.1111/jvh.12553.
    PubMed     Text format     Abstract available


  317. FULOP B, Mihm U, Rohde P, Buggisch P, et al
    Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type.
    J Viral Hepat. 2016 Jun 26. doi: 10.1111/jvh.12562.
    PubMed     Text format     Abstract available


  318. ZHOU YH
    Occult hepatitis B virus infection, or occult cross-contamination, in children of HBsAg-positive mothers.
    J Viral Hepat. 2016 Jun 23. doi: 10.1111/jvh.12559.
    PubMed     Text format    


  319. SHI R, Soomro MH, She R, Yang Y, et al
    Evidence of Hepatitis E virus breaking through the blood-brain barrier and replicating in the central nervous system.
    J Viral Hepat. 2016 Jun 21. doi: 10.1111/jvh.12557.
    PubMed     Text format     Abstract available


  320. YOUNOSSI ZM, Stepanova M, Sulkowski M, Naggie S, et al
    Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
    J Viral Hepat. 2016 Jun 13. doi: 10.1111/jvh.12554.
    PubMed     Text format     Abstract available


  321. GANE E, Ben Ari Z, Mollison L, Zuckerman E, et al
    Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection.
    J Viral Hepat. 2016 Jun 12. doi: 10.1111/jvh.12552.
    PubMed     Text format     Abstract available


  322. JOO EJ, Yeom JS, Kwon MJ, Chang Y, et al
    Insulin resistance increases loss of antibody to hepatitis B surface antigen in nondiabetic healthy adults.
    J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12556.
    PubMed     Text format     Abstract available


  323. DEBROY S, Hiraga N, Imamura M, Hayes CN, et al
    Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
    J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12551.
    PubMed     Text format     Abstract available


  324. GREBELY J, Litwin A, Dore GJ
    Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.
    J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12550.
    PubMed     Text format    


    May 2016
  325. WEISSENBORN K, Tillmann HL
    HCV encephalopathy - an artefact due to medical care?
    J Viral Hepat. 2016 May 26. doi: 10.1111/jvh.12547.
    PubMed     Text format     Abstract available


  326. MIZOKAMI M, Dvory-Sobol H, Izumi N, Nishiguchi S, et al
    Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    J Viral Hepat. 2016 May 15. doi: 10.1111/jvh.12549.
    PubMed     Text format     Abstract available


  327. TESHALE EH, Xing J, Moorman A, Holmberg SD, et al
    Higher all-cause hospitalization among patients with chronic hepatitis C: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2013.
    J Viral Hepat. 2016 May 15. doi: 10.1111/jvh.12548.
    PubMed     Text format     Abstract available


  328. LOWRY D, Burke T, Galvin Z, Ryan JD, et al
    Is psychosocial and cognitive dysfunction misattributed to the virus in hepatitis C infection? Select psychosocial contributors identified.
    J Viral Hepat. 2016 May 11. doi: 10.1111/jvh.12544.
    PubMed     Text format     Abstract available


  329. LIM EJ, Chin R, Nachbur U, Silke J, et al
    Hepatitis C-induced hepatocyte apoptosis following liver transplantation is enhanced by immunosuppressive agents.
    J Viral Hepat. 2016 May 11. doi: 10.1111/jvh.12541.
    PubMed     Text format     Abstract available


  330. DEUFFIC-BURBAN S, Obach D, Canva V, Pol S, et al
    Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
    J Viral Hepat. 2016 May 4. doi: 10.1111/jvh.12546.
    PubMed     Text format     Abstract available


    April 2016
  331. KATOONIZADEH A, Sharafkhah M, Ostovaneh MR, Norouzi A, et al
    Immune responses to hepatitis B immunization 10-18 years after primary vaccination: a population-based cohort study.
    J Viral Hepat. 2016 Apr 29. doi: 10.1111/jvh.12543.
    PubMed     Text format     Abstract available


  332. RAZAVI H
    Making the case for looking beyond WHO estimates for the global burden of hepatitis C and B.
    J Viral Hepat. 2016 Apr 5. doi: 10.1111/jvh.12539.
    PubMed     Text format     Abstract available


  333. EL-SERAG HB, Kramer J, Duan Z, Kanwal F, et al
    Epidemiology and outcomes of hepatitis C infection in elderly US Veterans.
    J Viral Hepat. 2016 Apr 3. doi: 10.1111/jvh.12533.
    PubMed     Text format     Abstract available


  334. PU Z, Li D, Wang A, Su H, et al
    Epidemiological characteristics of the carriers with coexistence of HBsAg and anti-HBs based on a community cohort study.
    J Viral Hepat. 2016;23:286-93.
    PubMed     Text format     Abstract available


  335. SADEGHI A, Yahyapour Y, Poortahmasebi V, Shahmoradi S, et al
    Clearance of HBV DNA in immunized children born to HBsAg-positive mothers, years after being diagnosed with occult HBV infection.
    J Viral Hepat. 2016;23:282-5.
    PubMed     Text format     Abstract available


    March 2016
  336. LU M, Li J, Rupp LB, Holmberg SD, et al
    Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma.
    J Viral Hepat. 2016 Mar 30. doi: 10.1111/jvh.12538.
    PubMed     Text format     Abstract available


  337. BASNAYAKE SK, Easterbrook PJ
    Wide variation in estimates of global prevalence and burden and death estimates from chronic HBV, HCV and coinfection with HIV in literature.
    J Viral Hepat. 2016 Mar 30. doi: 10.1111/jvh.12519.
    PubMed     Text format     Abstract available


  338. HARRIS RJ, Martin NK, Rand E, Mandal S, et al
    New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England.
    J Viral Hepat. 2016 Mar 29. doi: 10.1111/jvh.12529.
    PubMed     Text format     Abstract available


  339. BUNCHORNTAVAKUL C, Reddy KR
    Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.
    J Viral Hepat. 2016 Mar 28. doi: 10.1111/jvh.12534.
    PubMed     Text format     Abstract available


  340. GIUDICI F, Bertisch B, Negro F, Stirnimann G, et al
    Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12535.
    PubMed     Text format     Abstract available


  341. REN JP, Ying RS, Cheng YQ, Wang L, et al
    HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12537.
    PubMed     Text format     Abstract available


  342. MO H, Hedskog C, Svarovskaia E, Sun SC, et al
    Antiviral response and resistance analysis of treatment-naive HCV-infected patients receiving single and multiple doses of GS-9190.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12536.
    PubMed     Text format     Abstract available


  343. GRAY E, O'Leary A, Kieran JA, Fogarty E, et al
    Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.
    J Viral Hepat. 2016 Mar 21. doi: 10.1111/jvh.12532.
    PubMed     Text format     Abstract available


  344. SERVANT-DELMAS A, Abravanel F, Lefrere JJ, Lionnet F, et al
    New insights into the natural history of hepatitis E virus infection through a longitudinal study of multitransfused immunocompetent patients in France.
    J Viral Hepat. 2016 Mar 18. doi: 10.1111/jvh.12531.
    PubMed     Text format     Abstract available


  345. PERUMALSWAMI PV, Patel N, Bichoupan K, Ku L, et al
    High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens.
    J Viral Hepat. 2016 Mar 17. doi: 10.1111/jvh.12530.
    PubMed     Text format     Abstract available


  346. YOUNOSSI ZM, Stepanova M, Henry L, Younossi I, et al
    Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus.
    J Viral Hepat. 2016 Mar 14. doi: 10.1111/jvh.12528.
    PubMed     Text format     Abstract available


  347. RODRIGUEZ-TORRES M, Glass S, Hill J, Freilich B, et al
    GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
    J Viral Hepat. 2016 Mar 9. doi: 10.1111/jvh.12527.
    PubMed     Text format     Abstract available


  348. ROQUE CUELLAR MC, Garcia-Lozano JR, Sanchez B, Praena-Fernandez JM, et al
    Lymphomagenesis-related gene expression in B cells from sustained virological responders with occult hepatitis C virus infection.
    J Viral Hepat. 2016 Mar 4. doi: 10.1111/jvh.12526.
    PubMed     Text format     Abstract available


  349. STELMA F, Jansen L, Sinnige MJ, van Dort KA, et al
    HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy.
    J Viral Hepat. 2016 Mar 4. doi: 10.1111/jvh.12525.
    PubMed     Text format     Abstract available


  350. RAJBHANDARI R, Barton K, Juncadella AC, Rubin AK, et al
    Discontinuity of care for mothers with chronic hepatitis B diagnosed during pregnancy.
    J Viral Hepat. 2016 Mar 4. doi: 10.1111/jvh.12524.
    PubMed     Text format     Abstract available


  351. ZAYED N, Gamal Eldeen H, Elmakhzangy H, Seif M, et al
    Therapeutic outcome of 6198 interferon-naive Egyptian patients with chronic hepatitis C: a real-life experience and lessons to be learned in DAAs' era.
    J Viral Hepat. 2016 Mar 3. doi: 10.1111/jvh.12514.
    PubMed     Text format     Abstract available


  352. VISVANATHAN K, Lang T, Ryan K, Wilson R, et al
    Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients.
    J Viral Hepat. 2016;23:170-9.
    PubMed     Text format     Abstract available


    February 2016
  353. NINOMIYA M, Kondo Y, Kimura O, Funayama R, et al
    The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12522.
    PubMed     Text format     Abstract available


  354. PEVELING-OBERHAG J, Arcaini L, Bankov K, Zeuzem S, et al
    The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12518.
    PubMed     Text format     Abstract available


  355. WOODE ME, Abu-Zaineh M, Perriens J, Renaud F, et al
    Potential market size and impact of hepatitis C treatment in low- and middle-income countries.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12516.
    PubMed     Text format     Abstract available


  356. HARRIS M, Ward E, Gore C
    Finding the undiagnosed: a qualitative exploration of hepatitis C diagnosis delay in the United Kingdom.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12513.
    PubMed     Text format     Abstract available


  357. CHEN HH, Liu PF, Tsai HH, Yen RF, et al
    Re: Wangensteen et al. of a letter on 'Hepatitis C virus infection: a risk factor for Parkinson's disease.'
    J Viral Hepat. 2016 Feb 23. doi: 10.1111/jvh.12521.
    PubMed     Text format    


  358. WANGENSTEEN KJ, Krawitt EL, Hamill RW, Boyd JT, et al
    Hepatitis C virus infection: a risk factor for Parkinson's disease.
    J Viral Hepat. 2016 Feb 23. doi: 10.1111/jvh.12517.
    PubMed     Text format    


  359. SCHNIER C, Wild S, Kurdi Z, Povey C, et al
    Matched population-based study examining the risk of type 2 diabetes in people with and without diagnosed hepatitis C virus infection.
    J Viral Hepat. 2016 Feb 22. doi: 10.1111/jvh.12520.
    PubMed     Text format     Abstract available


  360. KONERMAN MA, Brown M, Zheng Y, Lok AS, et al
    Dynamic prediction of risk of liver-related outcomes in chronic hepatitis C using routinely collected data.
    J Viral Hepat. 2016 Feb 19. doi: 10.1111/jvh.12509.
    PubMed     Text format     Abstract available


  361. DRAVE SA, Debing Y, Walter S, Todt D, et al
    Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells.
    J Viral Hepat. 2016 Feb 19. doi: 10.1111/jvh.12515.
    PubMed     Text format     Abstract available


  362. AHN SH, Lim YS, Lee KS, Paik SW, et al
    A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
    J Viral Hepat. 2016 Feb 10. doi: 10.1111/jvh.12499.
    PubMed     Text format     Abstract available


  363. HAWKS L, Norton BL, Cunningham CO, Fox AD, et al
    The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic.
    J Viral Hepat. 2016 Feb 9. doi: 10.1111/jvh.12512.
    PubMed     Text format     Abstract available


  364. GISA A, Suneetha PV, Behrendt P, Pischke S, et al
    Cross-specific T-cell responses in acute hepatitis E virus (HEV) infection.
    J Viral Hepat. 2016 Feb 8. doi: 10.1111/jvh.12495.
    PubMed     Text format     Abstract available


  365. MEISSNER EG, Kohli A, Virtaneva K, Sturdevant D, et al
    Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12510.
    PubMed     Text format     Abstract available


  366. FALADE-NWULIA O, Mehta SH, Lasola J, Latkin C, et al
    Public health clinic-based hepatitis C testing and linkage to care in baltimore.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12507.
    PubMed     Text format     Abstract available


  367. YOUNOSSI ZM, Bacon BR, Dieterich DT, Flamm SL, et al
    Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12506.
    PubMed     Text format     Abstract available


  368. BOGLIONE L, Cariti G, Di Perri G, D'Avolio A, et al
    Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all?
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12502.
    PubMed     Text format    


  369. PAPATHEODORIDIS G, Thomas HC, Golna C, Bernardi M, et al
    Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.
    J Viral Hepat. 2016;23 Suppl 1:1-12.
    PubMed     Text format     Abstract available


  370. MINA MM, Cameron B, Luciani F, Vollmer-Conna U, et al
    Natural killer cells in highly exposed hepatitis C-seronegative injecting drug users.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12511.
    PubMed     Text format     Abstract available


  371. BROERING R, Trippler M, Werner M, Real CI, et al
    Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12508.
    PubMed     Text format     Abstract available


  372. POITEAU L, Soulier A, Rosa I, Roudot-Thoraval F, et al
    Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12501.
    PubMed     Text format     Abstract available


  373. IDRISSI ME, Hachem H, Koering C, Merle P, et al
    HBx triggers either cellular senescence or cell proliferation depending on cellular phenotype.
    J Viral Hepat. 2016;23:130-8.
    PubMed     Text format     Abstract available


    January 2016
  374. STUBBS A, Naylor P, Ravindran K, Benjaram S, et al
    Racial diversity in mortality and morbidity in urban patients with hepatitis C.
    J Viral Hepat. 2016 Jan 28. doi: 10.1111/jvh.12504.
    PubMed     Text format     Abstract available


  375. VIDAL LL, Soares MA, Santos AF
    NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naive subjects.
    J Viral Hepat. 2016 Jan 18. doi: 10.1111/jvh.12503.
    PubMed     Text format     Abstract available


  376. PFLUGRAD H, Meyer GJ, Dirks M, Raab P, et al
    Cerebral microglia activation in hepatitis C virus infection correlates to cognitive dysfunction.
    J Viral Hepat. 2016 Jan 15. doi: 10.1111/jvh.12496.
    PubMed     Text format     Abstract available


  377. ORTEGA-PRIETO AM, Dorner M
    The expanding toolbox for hepatitis C virus research.
    J Viral Hepat. 2016 Jan 13. doi: 10.1111/jvh.12500.
    PubMed     Text format     Abstract available


  378. SHRESTHA A, Lama TK, Gupta BP, Sapkota B, et al
    Hepatitis E virus outbreak in postearthquake Nepal: is a vaccine really needed?
    J Viral Hepat. 2016 Jan 12. doi: 10.1111/jvh.12505.
    PubMed     Text format    


  379. VELAY A, Jeulin H, Eschlimann M, Malve B, et al
    Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.
    J Viral Hepat. 2016 Jan 6. doi: 10.1111/jvh.12498.
    PubMed     Text format     Abstract available


  380. FOSTER GR
    The Journal Of Viral Hepatitis 2016.
    J Viral Hepat. 2016;23:4.
    PubMed     Text format    


    December 2015
  381. DUARTE-ROJO A, Fischer SE, Adeyi O, Zita D, et al
    Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.
    J Viral Hepat. 2015 Dec 29. doi: 10.1111/jvh.12494.
    PubMed     Text format     Abstract available


  382. ZHANG S, Ma Q, Liang S, Xiao H, et al
    Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China.
    J Viral Hepat. 2015 Dec 10. doi: 10.1111/jvh.12482.
    PubMed     Text format     Abstract available


  383. ZHOU X, Xu L, Wang W, Watashi K, et al
    Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.
    J Viral Hepat. 2015 Dec 1. doi: 10.1111/jvh.12491.
    PubMed     Text format     Abstract available


    November 2015
  384. YOUNG KL, Huang W, Horsburgh CR, Linas BP, et al
    Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission.
    J Viral Hepat. 2015 Nov 17. doi: 10.1111/jvh.12489.
    PubMed     Text format     Abstract available


  385. FOSTER GR, Ferenci P, Asselah T, Mantry P, et al
    Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.
    J Viral Hepat. 2015 Nov 17. doi: 10.1111/jvh.12485.
    PubMed     Text format     Abstract available


    August 2015
  386. ATHANASAKIS K, Petrakis I, Kyriopoulos J
    'HepConomics': cost-effective, indeed, but how can we pay for it?
    J Viral Hepat. 2015;22:682.
    PubMed     Text format    


    July 2015
  387. CHOLONGITAS E, Vasiliadis T, Goulis I, Fouzas I, et al
    Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease.
    J Viral Hepat. 2015;22:574-80.
    PubMed     Text format     Abstract available


    May 2015
  388. ZENG H, Liu H, Wan G, Wang X, et al
    Answer to 'Misdiagnosis of patients may be derived from the interfering factors and used cut-offs in indexes'.
    J Viral Hepat. 2015;22:513-4.
    PubMed     Text format    


  389. COBAN M, Sertoglu E, Kayadibi H
    Misdiagnosis of patients may be derived from the interfering factors and used cut-offs in indexes.
    J Viral Hepat. 2015;22:512.
    PubMed     Text format    


    April 2015
  390. JOHANNESSEN A
    Where we are with point-of-care testing.
    J Viral Hepat. 2015;22:362-5.
    PubMed     Text format     Abstract available


  391. CAREY I, Bruce M, Horner M, Zen Y, et al
    HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy.
    J Viral Hepat. 2015;22:441-52.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: